All the news Showing 10 of 119 articles.Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources DAA treatment reduces the risk of death and liver cancer in France Keith Alcorn / 12 February 2019 Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to results of one of the largest studies ... Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost Michael Carter / 01 February 2019 Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ... Sofosbuvir/ledipasvir cures most young children with hepatitis C Liz Highleyman / 13 November 2018 Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented at the ... Successful hepatitis C treatment lowers risk of cardiovascular events Liz Highleyman / 25 October 2018 Treatment for hepatitis C, especially if it leads to a cure, is associated with a reduced risk of cardiovascular events such as congestive heart failure, heart attacks and strokes, according to research presented ... Psychological relief is the most important benefit of a hepatitis C cure for patients Roger Pebody / 13 September 2018 When asked to describe what their hepatitis C cure meant to them, Australians who had recently completed treatment emphasised an improved sense of psychological wellbeing, according to a qualitative study recently published in ... Reinfection risk after hepatitis C treatment higher in recent drug users Keith Alcorn / 07 September 2018 Reinfection with hepatitis C after successful treatment is more common in younger people who inject drugs and recent and former drug users are at greatest risk of reinfection, a cohort study in ... DAAs safe and effective in elderly people with HCV Michael Carter / 05 September 2018 Treatment with direct-acting antivirals (DAAs) is safe and effective in elderly people with hepatitis C virus (HCV) infection, according to German research published in Drugs & Aging. Elderly people (aged 70 years ... DAA therapy for HCV patients without serious liver disease has significant survival benefits Michael Carter / 26 July 2018 Successful HCV treatment with direct-acting antivirals (DAAs) significantly reduces the risk of death for people who do not have advanced liver disease, investigators report in Hepatology. A sustained virologic response ... People with mental health and substance use issues still less likely to receive HCV therapy Michael Carter / 24 July 2018 The proportion of people with chronic hepatitis C virus (HCV) infection who receive antiviral treatment has increased substantially since the introduction of direct-acting antivirals (DAAs), investigators from the United States report in ... Advent of DAAs accompanied by dramatic improvement in survival after HCV-related liver transplant Michael Carter / 18 July 2018 Survival among people with hepatitis C virus (HCV) undergoing liver transplant has improved significantly since the introduction of direct-acting antivirals (DAAs), investigators from Catalonia report in the Journal of Hepatology. Thanks to DAAs, there ... ← Prev12345...12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive